Check out this company and let me know what you think. I just listened to a conference call which sounded like this company has great growth potential.
http://biz.yahoo.com/iw/051117/0101685.html
http://www.sunwin.biz/
This news yestserday caused a stir up just over 19% on great volume.
Also,....an Elite g pick ;D
2005-11-29 08:00:17
Shandong Province Government Submits Fast Track Application for New Treatment for Avian Flu Virus
FORT LAUDERDALE, FL and QUFU, CHINA -- (MARKET WIRE) -- 11/29/05 -- Sunwin International
Neutraceuticals, Inc. (OTC BB: SUWN), an industry leader in the production
and distribution of Chinese herbs, veterinary medicines and low calorie
natural sweetener (Stevia) in China, will seek approval for "Hypericin" as
a new veterinary medical application to treat avian flu. The Department of
Livestock Farming for Shandong Province Government has recently submitted a
fast-track application to the Livestock Farming Bureau of China Ministry of
Agriculture for approval of Hypericin on behalf of Sunwin International
Neutraceuticals, Inc. as a new veterinary medicine to treat avian flu
virus. Hypericin is a derivative of St. Johns Wort, which is an English
word for a Chinese herb manufactured by Sunwin. Sunwin has manufactured
Hypericin since 1997.
In recent laboratory tests, Hypericin has proven effective as a treatment
for poultry infected with strands of the avian flu. The South China
Agricultural University has recently finished a clinic test of a medicine
developed by the Chinese Academy of Agricultural Sciences. The result
showed hypericin, which is isolated from hypericum perforatum, had cured
all poultry infected by the deadly H5N1 avian flu for the experiment. The
in vitro experiments indicated that when H5N1 and H9N2 avian flu viruses
were treated with hypericin at 3.72 mg/ml for 30 minutes, hypericin killed
100% of the viruses. When these viruses were treated with hypericin at
0.744 mg/ml for 10 minutes, hypericin killed over 99.99% of the viruses.
Laiwang Zhang, President and Chairman of Sunwin International
Neutraceuticals, Inc., stated, "The approval could pave the way for
Hypericin as a commercial application for the treatment of livestock
populations in China. If approved, the demand for Hypericin should
increase substantially worldwide. Furthermore, the new application can
lead to successful development of the new medicine will not only help
prevent the epidemic on birds and control the spread in those places which
have reported outbreaks, but also can give some idea and experience to the
development of new drug for human."
Mr. Zhang concluded, "We expect the demand for hypericin is tremendous for
months to come upon the approval, as the Chinese government has announced
it would spend $1 billion in the fight against bird flu virus. Currently,
the company is producing several tons every year and is able to produce
approximately 100 to 150 tons per year. The company is able to add the
production up to 300 tons production capability per year within months if
the market demand increases. The market price of hypericin is approximately
$50,000 per ton."
About Sunwin International Neutraceuticals, Inc.
Sunwin International Neutraceuticals, Inc. (OTC BB: SUWN) is engaged in the
areas of essential traditional Chinese medicine, 100% organic herbal
medicine, neutraceutical products, low-calorie natural sweetener (Stevia),
and veterinary medicines and feeds prepared from 100% organic herbal
ingredients. As an industry leader in agricultural processing, Sunwin has
built an integrated global firm with the sourcing and production
capabilities to meet the needs of consumers throughout the world. Sunwin
also makes such value-added products as specialty veterinary food
ingredients and specialty feed ingredients. The Sunwin family works closely
with consumer to provide a quality and a hybrid mix of agricultural
products and services that meet growing demand. In 2002, Sunwin was
recognized as one of the first 2,000 state-level companies that China
authorized as the most important innovative high-tech pioneer businesses by
the Chinese central government. In 2002, Sunwin was awarded as one of 2002
state-level biological product manufacturers in China. In 2003, Sunwin
ranked as one of the top 50 companies of China Animal Related Health Care
Product Pharmaceutical Industry. In 2003, Sunwin received award of Shandong
Top-Ten Innovative, High-Tech Businesses by the Province Government of
Shandong. For more info about Sunwin, please visit http://www.sunwin.biz
And a bit more news this a.m
2005-11-30 08:00:16
Sunwin International Neutraceuticals, Inc. to Present at Friedland Investment Events' Micro-Cap Conference in New York
FORT LAUDERDALE, FL and QUFU, CHINA -- (MARKET WIRE) -- 11/30/05 -- Sunwin International
Neutraceuticals, Inc. (OTC BB: SUWN), an industry leader in the production
and distribution of Chinese herbs, veterinary medicines and low calorie
natural sweetener (Stevia) in China, has been invited to present at this
year's Friedland Investment Events' Micro-Cap 2005 Conference. This
financial conference will be held at the Doubletree Metropolitan Hotel in
New York City on December 6, 2005.
Sunwin International Neutraceuticals, Inc.'s presentation by its US
representative will include a review of current operations, the progress of
their main products and most importantly the Company's plans for the
future. All shareholders and prospective investors are invited to attend.
Commenting on the Company's participation at the Micro-Cap Conference,
Laiwang Zhang, President and Chairman of Sunwin International
Neutraceuticals, Inc. stated, "Sunwin is looking forward to presenting at
this Friedland Investment Events' conference. We are determined to
increase shareholder value. Management believes our common stock is
substantially undervalued compared to its peers. The event will provide
the Company with the opportunity to introduce a select group of invited
representatives of buy-side and sell-side firms to our Company."
About Sunwin International Neutraceuticals, Inc.
Sunwin International Neutraceuticals, Inc. (OTC BB: SUWN) is engaged in the
areas of essential traditional Chinese medicine, 100% organic herbal
medicine, neutraceutical products, low-calorie natural sweetener (Stevia),
and veterinary medicines and feeds prepared from 100% organic herbal
ingredients. As an industry leader in agricultural processing, Sunwin has
built an integrated global firm with the sourcing and production
capabilities to meet the needs of consumers throughout the world. Sunwin
also makes such value-added products as specialty veterinary food
ingredients and specialty feed ingredients. The Sunwin family works closely
with consumer to provide a quality and a hybrid mix of agricultural
products and services that meet growing demand. In 2002, Sunwin was
recognized as one of the first 2,000 state-level companies that China
authorized as the most important innovative high-tech pioneer businesses by
the Chinese central government. In 2002, Sunwin was awarded as one of 2002
state-level biological product manufacturers in China. In 2003, Sunwin
ranked as one of the top 50 companies of China Animal Related Health Care
Product Pharmaceutical Industry. In 2003, Sunwin received award of Shandong
Top-Ten Innovative, High-Tech Businesses by the Province Government of
Shandong. For more info about Sunwin, please visit http://www.sunwin.biz
About Friedland Investment Events
Friedland Investment Events LLC is the world's largest sponsor of financial
and investment events, sponsoring over 280 events annually, in 28 US cities
and 3 European cities. These events include all-day conferences,
breakfasts, luncheons and cocktail receptions.
Friedland Investment Events LLC, is an affiliate of Friedland Corporate
Investor Services LLC and Friedland Capital Inc.
(www.friedlandworldwide.com)
Friedland Corporate Investor Services provides financial marketing and
investor awareness programs to privately-held and publicly-held companies,
as well as sponsors of investment programs and products.
Friedland Capital Inc. is a US based merchant bank and advisory firm with
offices in New York, Dallas, Denver, Vancouver, Beijing and Guangzhou.
Among its activities, Friedland Capital provides corporate finance advisory
services to enable publicly-traded and privately-held emerging growth
companies, as well as sponsors of investment programs worldwide to achieve
their short-term capital goals, and to realize their long-term business
objectives.
I went ahead and bought this morning based on technicals/hype only.
Applaud.
My girlfriend loves Stevia and goes out of her way to find it!!
Getting in this morning-
Sounds like great news!
2005-12-07 08:00:18
Local Government Designates Veterinary Disinfectants Produced by Sunwin International Neutraceuticals as a Primary Resp
FORT LAUDERDALE, FL and QUFU, CHINA -- (MARKET WIRE) -- 12/07/05 -- Sunwin International
Neutraceuticals, Inc. (OTC BB: SUWN), an industry leader in the production
and distribution of Chinese herbs, veterinary medicines and low calorie
natural sweetener (Stevia) in China, announces the Jining City Government
has designated Sunwin's veterinary disinfectants as a primary response to
combat the avian flu virus. Jining City, situated in the southwestern
region of the Shandong Province, administers 12 districts, counties and
cities including Qufu where Sunwin is headquartered. The Jining City
government services a population of 7.56 million within 4,200 square miles.
Sunwin is the only provider of veterinary disinfectants in Jining City.
Sunwin has developed a series of veterinary disinfectants employing
traditional Chinese herbal medicine devised to combat the avian flu virus.
The new line of disinfectants has been proven effective in inhibiting the
spread of the H5N1 and H9N2 strands of the avian flu. The new series of
veterinary disinfectants meets national sanitary standards established by
the central government. Recently, Sunwin announced that the department of
Livestock and Farming for Shandong Province Government has submitted a
fast-track application to the Livestock Farming Bureau of China Ministry of
Agriculture on behalf of Sunwin International Neutraceuticals, Inc.
Laiwang Zhang, President and Chairman of Sunwin International
Neutraceuticals, Inc., stated, "The central government is mobilizing to
prepare for a potential avian flu pandemic. Following the wave of reported
cases of avian flu in China, we hope to witness strong demand for our
products. Sunwin is committed to providing a solution to combat the avian
flu."
About Sunwin International Neutraceuticals, Inc.
Sunwin International Neutraceuticals, Inc. (OTC BB: SUWN) is engaged in the
areas of essential traditional Chinese medicine, 100% organic herbal
medicine, neutraceutical products, low-calorie natural sweetener (Stevia),
and veterinary medicines and feeds prepared from 100% organic herbal
ingredients. As an industry leader in agricultural processing, Sunwin has
built an integrated global firm with the sourcing and production
capabilities to meet the needs of consumers throughout the world. Sunwin
also makes such value-added products as specialty veterinary food
ingredients and specialty feed ingredients. The Sunwin family works closely
with consumers to provide a quality and a hybrid mix of agricultural
products and services that meet growing demand. In 2002, Sunwin was
recognized as one of the first 2,000 state-level companies that China
authorized as the most important innovative high-tech pioneer businesses by
the Chinese central government. In 2002, Sunwin was awarded as one of 2002
state-level biological product manufacturers in China. In 2003, Sunwin
ranked as one of the top 50 companies of China Animal Related Health Care
Product Pharmaceutical Industry. In 2003, Sunwin received award of Shandong
Top-Ten Innovative, High-Tech Businesses by the Province Government of
Shandong. For more info about Sunwin, please visit http://www.sunwin.biz
Quote from: gmarc66 on November 30, 2005, 08:28:33 AM
This news yesterday caused a stir up just over 19% on great volume.
Also,....an Elite g pick ;D
How much better can you get? "An EliteG Pick" ;)
I got me some! ;D
How did EliteG put it,I think it went like this...."It Has Blast Off Capability" :o
Words of EliteG, below......
i really like this chart.. think it does have blast off capability and then I did some research on the company and the news.. think this is one of the best pennies out there .
Go check it out on his thread here....
http://www.3stocksonfire.org/trading/index.php?topic=3837.60
He also holds this in his portfolio, check it out here......
http://www.3stocksonfire.org/trading/index.php?topic=3836.30
Setravis..i love it when u get in a stock and give it your thumbs up! ;D Both u and Eliteg...wow..thats always makes me feel better ;D
It has been slow but, holding...and last time it was with MBAH...slow..but, then it doubled a few weeks(month or so later)...so, i will be patient with SUNW...maybe add a little more..i only bought a little bit.
Got to make up for the huge loss i will be taking on DIAAF tomorrow...all these rumours kill a pps!
Good luck to you!! ;D
julia
Well, with Stravis and elite both behind this i threw what little i had left into it, hoping for a nice takeoff. And if julia's in on this too, that is surely the kiss of death. Together we can act like the rubber band on a slingshot, we'll buy some shares and pull this baby down, let everyone accumulate at a low point, then we'll sell, shooting this baby to the moon. Just make sure you drop some coins in our big red pots as we ring the bell outside of Walmart.
Bob
HA HA Supergeek...u said it!!! ;D ;D ;D ;D ;D
can anyone spare a dime?
glta
julia
Well, what's up ?
I'm at the break even point at this time.
Spare a dime to me please..... ;D
I guess a buy closer to the ascending trendline would have been better. At least it's staying above the 10dma which it hasn't strayed too far from during this run...
Looking good :D...when i saw the 10Q come out yesterday afternoon I saw a little surge in volume and pps...hoping today is a big surge in both!! GLTA holders ;D
2005-12-15 08:00:11
Sunwin International Neutraceuticals Achieves Record Revenues and Earnings for Q2 of Fiscal Year 2006, EPS of 0.02
FORT LAUDERDALE, FL and QUFU, CHINA -- (MARKET WIRE) -- 12/15/05 -- Sunwin International
Neutraceuticals, Inc. (OTC BB: SUWN), an industry leader in the production
and distribution of Chinese herbs, veterinary medicines and low calorie
natural sweetener (Stevia) in China, today announced record financial
results for the second quarter ended October 31, 2005 of fiscal year 2006.
The Company recorded revenues of $4.052 million for the quarter ended
October 31, 2005; this represents a 28% increase from $3.159 million
recorded for the same period in fiscal 2005. Net income surged to
approximately $898,530, a 1,325% increase over the $63,030 in net income
reported for the same period in fiscal year 2005. This translates to an
EPS of $0.02 per share for the second quarter. The improved results are a
direct response to the increased demand of Sunwin's products as well as a
result of new cost controlling measures. For more details about Sunwin's
financial performance, please review the 10-QSB filed with the United
States Securities and Exchange Commission.
As of the second quarter of the fiscal year 2006, the Company had $2.38
million in cash and cash equivalents, a 249% increase from $0.682 million
recorded for the same period in fiscal year 2005. Shareholder equity
increased to $7.096 million or book value of $0.16 per share, its highest
level ever, a 67% increase from $4.247 million recorded for the same period
in fiscal year 2005.
Laiwang Zhang, Chairman and President of Sunwin, commented, "We are very
pleased with the financial performance for the second quarter. We continue
to achieve record revenue and earning growth in our core businesses, while
effectively controlling expenses, improving profitability and strengthening
the balance sheet. We are very excited about the coming fiscal years, as
the Company has made significant investments to upgrade its manufacturing
facilities. Management is very optimistic about our prospects, as demand
continues to accelerate for our low-calorie natural sweetener (Stevia),
Chinese herbs, and veterinary medicines worldwide. The upgraded
manufacturing facilities will assure our leading position in the
industries, thereby contributing to substantial growth in our sales and
earnings. We expect to substantially increase our sales and profit margins
in all of the three divisions in the coming fiscal quarters and years."
Not sure why SUWN isnt moving..how long are we supposed to hold...with all the good news, it still doesn't seem to be going anywhere...getting sleepy.
Anyway, more news:
2005-12-16 08:00:11
Sunwin International Neutraceuticals Attains GMP Certification From the China Ministry of Agriculture
FORT LAUDERDALE, FL and QUFU, CHINA -- (MARKET WIRE) -- 12/16/05 -- Sunwin International
Neutraceuticals, Inc. (OTC BB: SUWN), an industry leader in the production
and distribution of Chinese herbs, veterinary medicines and low calorie
natural sweetener (Stevia) in China, has passed inspection at six
manufacturing facilities. The Good Manufacturing Practice inspection
("GMP") was performed by the China Ministry of Agriculture. The
inspections covered five veterinary medicine facilities and one Chinese
herb facility.
The Chinese central government mandates manufacturers of Chinese herbs and
veterinary medicines to comply with GMP standards by December 31, 2005.
Currently, it is estimated that only one third of Chinese manufacturers in
both industries are in compliance with the new mandate. Starting on
January 1, 2006, only products manufactured within GMP certified facilities
are available for sale in China.
Laiwang Zhang, Chairman and President of Sunwin, commented, "Sunwin has
invested substantial capital to upgrade its manufacturing facilities in
order to comply with the heightened standards mandated by the central
government. The successful GMP inspection is a milestone for our company.
Currently, we have 7 GMP certified manufacturing facilities that would
accommodate substantial growth for the next 2 to 3 years for both
veterinary medicine and Chinese herb medicine. We expect to witness a
surge in demand for our products as much of our competition is currently
unable to meet GMP standards."
C'mon Julia, what'd you expect with both of us owning this? Once it dips a little more so more 3SOF members can buy some I'm gonna sell and watch SEtravis and elite make a fortune. I think i've figured out my problem. If you're a fan of football you've no doubt heard of the Sports Illutrated cover curse or the chunky soup curse. well i think i have the 3SOF curse, i was having a great year right up until i paid for my membership. as soon as i hit enter i started making the worst decisions, Like loading up on EYII, buying back in on others during a slide. I sold out of eln at 8 because i thought i could make a few quick moves before it goes back up, so i missed a double well on its way to being a triple. I went from being Up 60% on the year to down 60% in 3 months. I need to reverse the curse, any red sox or white sox fans have any ideas?
Bob
What do you guys still think of this stock? I just put in a buy order at the bid price of .215 for 6976 shares ($1,500). So far it has yet to be filled.
Hi nmbr1ballr
You might want to check you're buy order if it's not being filled. Scottrade will not do order under 1.00 unless it's a limit order. Don't know you're broker but you might want to check that.
Ya I know. I use ameritrade and had it as a limit order. They just didn't want to sell so I canceled that order and replaced it with the ask price of .22 and was filled in just a few minutes. So I now own 6818 shares @ .22.
Already more volume before 11:00 then all day yesterday. Up 8% so far. 8)
Ive seen enough. Im In >:D
here's chart for today...so far. pretty bullish. more vol. will add some fire.
will it take out 0.26? only time will tell.
nothing really changed since my last post....tested 0.26 a few times. break of that will take this to 0.30, the most recent and the 52 week high.
if that's taken out, clear coasting to 0.50 IMO. :)
Merry Christmas and a Happy New Year 2006 to everybody on this excellent 3SOF board.
SUWN is up 20% at the moment. Was up a lil higher earlier. Already 2.2 million shares traded in the first 40 minutes. No news either, hmm...
Stock is doing very good recently. How high do you think it can go?
http://stockcharts.com/def/servlet/SC.web?c=suwn
Looking at stocks such as SQUM, XSNX and BRVO history, this may go to same levels of 0.7 before coming down. Technically volume is average and stock price is up. good signs... there are so many technical gurus here, would like to see their take on it.
- Dhiraj
This may explain why this stock is so hot :)
Press Release Source: Sunwin International Neutraceuticals, Inc.
WallStreet Research Continues Coverage of Sunwin International Neutraceuticals Inc. Shares With Speculative Strong Buy Recommendation at www.WallStreetResearch.org
Wednesday January 4, 10:55 am ET
NEW YORK, NY--(MARKET WIRE)--Jan 4, 2006 -- WallStreet Research, a prominent equity research boutique led by Alan Stone, Managing Director of Alan Stone & Company, LLC, announced today that it has released an update report continuing coverage with a speculative strong buy recommendation of Sunwin International Neutraceuticals, Inc. (OTC BB:SUWN.OB - News), a diversified global nutraceutical company. The complete analyst research report, together with the risks associated therewith and additional information about WallStreet Research, is available at www.WallStreetResearch.org.
Mr. Stone was formerly a securities analyst and assistant portfolio manager at Merrill Lynch Asset Management and an investment analyst at Prudential Insurance Company's Capital Markets Group. WallStreet Research specializes in the microcap and smallcap investment arena, looking for emerging growth companies with strong management, unique or proprietary technology products, significant market potential, financial strength, and outstanding long-term earnings growth possibilities. The firm has offices in Los Angeles, CA; Palm Beach, FL; and New York City, NY, and is well known for discovering undervalued companies and bringing them to the attention of the investment community.
Sunwin International Neutraceuticals, Inc. (www.sunwin.biz), headquartered in Qufu, in the Shandong Province of the People's Republic of China, is a diversified nutraceutical company engaged in the development, manufacturing and international sale of a variety of health products for humans and animals. The Company's agricultural processing expertise and convenient access to raw materials in select Chinese farmlands result in high-quality and cost-effective natural products that straddle the healthcare industry and the food & beverage marketplace. Products offered by the Company include a powerful low-calorie natural sweetener called stevioside, numerous herbal extracts rooted in traditional Chinese medicine (TCM), as well as a variety of veterinary medicines and feed supplements. Their innovative nature has in recent years earned state-level recognition and several industry awards for the Company. For the fiscal year ended April 30, 2005, the Company's revenues rose 11.3% to $12.1 million, and the net income increased 78% to $829,114, or $.02 per share. In the first six months of fiscal 2006 ended October 31, 2005, total revenues climbed 11.8% to $7,223,971, from $6,458,285 in comparable period in the previous year. Last September, the Company completed an upgrade and expansion of most of its manufacturing facilities, which not only increased stevioside production capacity to 300 tons per year, or a double-digit percentage share of the global demand, but also fulfilled GMP requirements mandated since the beginning of 2006 by the central government on producers of Chinese herb and veterinary medicines. Trading on the OTC Bulletin Board under the symbol SUWN, the Company is well positioned to immediately capitalize on the temporary competitive advantage resulting from the GMP certification and benefit from the overall growing health concerns among consumers globally, increasing popularity of organic foods and medicines, and the strong condition of the Chinese economy.
That was released Jan. 4th. Why the jump 2 weeks later after it came out?
I had to use above chart to show my reason for move in stock, I'm not saying this is the main reason why stock is moving but chart showed it was heading in an upward trend
Goodluck trading
i
Well Im not exactly how sure how to read charts besides things like volume. Its up another 13%.
I am up about 115% since I invested. Only wish I put in more.
I had been holding it for awhile and forgot i had at gtc sell order at .41, so it accidentally sold yesterday and couldn't cancel it in time....still made a profit, but would have been great to more than double it. ;D
Is it still going higher? ]
I like your chart analysis style Wrangler ;D
Glta ;D
julia
Thanks Julia for the comment also goodluck to all holding SUWN. While I was watching CNBC this morning SUWN came up on their ticker tape almost every third one. To bad all stock picks aren't this good, wish I would have caught the train on this one.
Applauds to all
This is Ground Control to Major SUWN: You've really made the grade, and the papers want to know whose shirt you wear! :o :o :o
What a rally these past two weeks! My rule of thumb with parabolic OTC stocks is to sell part of my position when I have a 3-bagger. My entry was .222 so if we see .666 tomorrow I'll probably sell half. Who else is still holding?
I'm here as well. Bought in at .22. I want to see if this can hit $1. If I see that it is dropping I will sell.
I took some time off... ;)
Haven't been on the website the last week to 10 days.
I'm still holding this little baby.....Who else is still in ?
My rule of thumb for parabolic OTC stocks is to sell part when I get a 3-bagger. For SUWN, that number would be .666 (aka the number of the beast). However, another rule of thumb I have is don't sell a runner on Monday morning because if it's running at the open it has a good chance of running through to the close. A better time to sell IMO is a Tuesday gap up after a Monday run. Thus, I am still holding all my SUWN. I will reevaluate just before the close and may take some profits there or may hold all for a gap up tomorrow.
I think I am going to hold off on selling for a couple days. I think this might be able to hit $1. If it does I will sell and reinvest in PTSC.
I tried to sell 30% of my position near the close at .78 but didn't get it. The bid was at .7802 with a couple bids at .78 for about a minute after I entered the order, but that is the inefficiency with trading OTC stocks. We'll see what tomorrow brings. The mythical 4-bagger stock has eluded me for a long time. My personal Moby Dick. A price of .888 would be a 4-bagger on SUWN. So close!!!$$$
Do OTC stocks trade after hours? According to cnn SUWN went down 15% after hours.
ballr - as you can see from today's open, that number you saw yesterday was an anomoly. OTC stocks don't trade after hours.
I sold 30% of my position at the open at .853. I'm glad those shares didn't get taken yesterday at .78! Then I went straight to my trade-tracking spreadsheet cause I had to see how cool that trade looked. 283.8% gain on those shares!! I hope my next sale is >300%, that would be sweet.
Hey Lucas, nice gain. You're welcome. As you can see, TA and FA mean nothing compared to my Catapult approach. You just point out the next stock you think looks promising, I'll buy and watch my initial investment cut in half within days then you back up the truck and buy a ton of shares, then i'll get depressed/impatient enough to sell and send you on the way to Richville USA. God forbid I sell EYII, A PO will immediately come out for 200 million code blues, it'll hit $10/share in seconds. Just give me a shout when you're looking to hire a butler.
Bob
Thanks SuperG - I'll keep you in mind when I need a stock beat down for a few days so I can get a better entry LOL ;)
I sold another 30% at .75. Thinking we may have seen the top this morning. I'll hold the final 40% for a few more days probably and see what happens. Maybe we get a retest of .85. Or maybe this is just a normal pullback on the way to new highs. Thus I don't want to sell my whole position.
Moving to greener pastures, check out ADZR. I nailed it!! Yesterday I posted that the chart and volume were starting to look ripe. Today it skyrockets, at one point up 200%! I bought at .07! Link to the 3SoF thread:
http://www.3stocksonfire.org/trading/index.php?topic=4438.0
i bot on the dip, and sold a little early...i thought maybe it was done for a while, but is now starting to gain a little steam. anyone think this can get over .90 in the coming weeks? it's seems to be trying to break out.
Early in the morning there was a huge seller. Brought the price down to .66. After that was over, the stock went straight back up. From down 15% to up 8%. I defanitly think it cna get over .90. I want to see $1 tomorrow or Wednesday.
Quote from: setravis on December 07, 2005, 09:08:54 PM
Quote from: gmarc66 on November 30, 2005, 08:28:33 AM
This news yesterday caused a stir up just over 19% on great volume.
Also,....an Elite g pick ;D
How much better can you get? "An EliteG Pick" ;)
I got me some! ;D
How did EliteG put it,I think it went like this...."It Has Blast Off Capability" :o
Words of EliteG, below......
i really like this chart.. think it does have blast off capability and then I did some research on the company and the news.. think this is one of the best pennies out there .
Go check it out on his thread here....
http://www.3stocksonfire.org/trading/index.php?topic=3837.60
He also holds this in his portfolio, check it out here......
http://www.3stocksonfire.org/trading/index.php?topic=3836.30
This baby is lovely...in since 0.235 The EliteG, is a"Stock Wizard"
Hey Setravis.....I know..isnt it pretty much true....if elite posts a stock pick..and for some reason it doesnt take off right away..just hold it...because usually and eventually it ends up leaving the station on a speed train...sometimes it takes a few days...sometimes weeks and sometimes months..but, be patient, cause then u'll be happy and rich! ;D....off the top of my head...NVAS and LBTN come to mind, and there were several others....Then of course we throw you into the mix once you've added your thumbs up and watch out!!! ;D ;D ;D
Wish i held this little guy a few days longer...my fault for putting in my sell orders ahead of time and forgetting about them...got to watch that...silly girl :)
Good luck and congrats to all those that made good money on this one...wouldn't it be nice if they were all like this?! ;D
hope all did well today ;D
julia
Lady you said a mouth full about the EliteG, The Wizard ! :o
He is truly a remarkable stock head full of knowledge. ;)
I hope your trading is going well this year, and you are making some good profits. ;D
Wish you all the best ! ;)
Thanks Buddy!! and working on it...still need lots of work..but, keep posting all these little lovelies and it will point me in the right direction ;D ;D
Hoping your doing amazing..i know u are! ;D
glta to all
julia
I was holding SUWN from 0.59 and sold today at 0.845 for a nice 43% profit. Considering my small capital, I did not make thousands, but for a newbie, I think I did pretty well.
I wanted to get back in if the stock got lower. I had put a buy order at 0.60 but SUWN never got that low today and I didn't keep an eye on it during the day. I could have had a very nice buy at 0.65, but oh well. I will definitely keep watching this little guy for another pullback (hopefully soon!)
Good luck to all holding SUWN!! :D
End of the day chart
Sold my last position at .64. I don't think the gap up will hold and I think yesterday and today are a technical bounce and the stock will go lower. Thank you SUNW and thank you EliteG for tipping SUNW!
Well, brilliant trader that I am it appears I sold at the low of day :-[ Though I can take some solace in that a large number of trades occurred between .64 and .645 this morning. And I can hang my hat on the fact my first two sales came on the day SUWN topped! $-)
Let's Rock and Roll
Hey Setravis..yes , i noticed this up today...and news just came in a very short while ago.
Wednesday, February 15 2006 11:25 AM, EST
Sunwin International Neutraceuticals Forms a US Subsidiary to Distribute Stevia in the US
FORT LAUDERDALE, FL and QUFU, CHINA -- (MARKET WIRE) -- 02/15/06 -- Sunwin International Neutraceuticals, Inc. (OTC BB: SUWN), an industry leader in the production and distribution of Chinese herbs, veterinary medicines and low calorie natural sweetener (Stevia) in China, has formed a wholly owned subsidiary, Sunwin Stevia International Corp, in order to aggressively market its Stevia throughout the US.
Stevia, a 100% natural sweetener, is extracted from the leaves of the Stevia rebaudiana plant, as a food additive which is used in various products such as beverages, foods, confections, and medicinal products in China and Japan. Forms of Stevia are approximately 300 times sweeter than general sucrose, with only 1/300th of the calories. Stevia is often referred to as the third generation of natural low calorie sweetener.
Mr. Laiwang Zhang, President and Chairman of Sunwin International, commented, "We are very excited about the potential that the US Stevia distribution can bring to the company. We have contracted marketing professionals to guide our operations in the US. We will start our operations in Florida and California. We believe there are tremendous needs for our Stevia in the US marketplace, as there are over 20.8 million diabetic patients and an additional 41 million Americans with pre-diabetes in the US."
Mr. Zhang further stated, "Obesity is at epidemic proportions, with the largest increase in young children. Stevia use by diabetics as well as health conscious individuals in the US has been growing substantially over the last 15 years. More and more parents are becoming aware of shopping for food products and supplements with reduced sugar levels. The average Stevia user spends $80 on product per year."
pullback, time for reentry ?
http://tinyurl.com/c23mo
highest ever weekly close....
look at the chart...RSI has taken a brief hiatus and has resumed uptrend...break of $0.94 will propel this to $1.50 or even higher (kinda like XSNX...??)
http://stockcharts.com/def/servlet/SC.web?c=SUWN,uu[w,a]waclyyay[de][pc20][vc60][iUb14!Lc20]&pref=G
how many bulletin board companies do you find that actually deliver solid earnings and also cater to the largest consumer market in the world...China??
and now, distribution of stevia in USA to commence...and resumption of fears of bird flu
chart link did not come up as I liked...here u go again:
http://stockcharts.com/def/servlet/SC.web?c=SUWN,uu[w,a]waclyyay[de][pc20][vc60][iUb14!Lc20]&pref=G
dang...chart link's not working..here' the chart itself. ;)
Vic - I was liking the setup on the daily chart, but looking at the weekly chart you posted I think SUWN may need more time to consolidate before it pushes to new highs. That's my guess.
btw regarding the problem of broken links: when you try to post a long link like that, it usually end up breaking. Use http://tinyurl.com/. It's free and simple. You copy and paste your long link into tinyurl and it converts it into s tiny link. For example, the link you tried to post would be: http://tinyurl.com/pbvzb
Technically speaking it is a bullish engulfing.
the bounce back up on the RSI on the 2 yr. weekly chart tells me this is going to be a sustained bullish move up.
i got in at the break of $0.65 and am continuing to hold for a bigger move...kinda like XSNX...
good luck. :)
strong up move today on very good volume.
testing recent highs of $0.97, break of that will take this to better levels above $1.00 - kinda like XSNX in my opinion.
MACD and RSI indicate lots of room to run still.
Quote from: setravis on December 07, 2005, 09:08:54 PM
Quote from: gmarc66 on November 30, 2005, 08:28:33 AM
This news yesterday caused a stir up just over 19% on great volume.
Also,....an Elite g pick ;D
How much better can you get? "An EliteG Pick" ;)
I got me some! ;D
How did EliteG put it,I think it went like this...."It Has Blast Off Capability" :o
Words of EliteG, below......
i really like this chart.. think it does have blast off capability and then I did some research on the company and the news.. think this is one of the best pennies out there .
Go check it out on his thread here....
http://www.3stocksonfire.org/trading/index.php?topic=3837.60
He also holds this in his portfolio, check it out here......
http://www.3stocksonfire.org/trading/index.php?topic=3836.30
Let's not forget this baby!!
I'm with you here......
Volume: 2,980,584
Avg Vol (3m): 2,049,060
too late for investing in SUWN?
SUWN: New 52-Wk High @ $1.245 up 15.81%
Friday , February 24, 2006 14:55 ET
This is the 1st 52 WEEK HIGH alert for SUWN in the past 7 calendar days.
The share price for Sunwin International Neutraceuticals, Inc. (OTCBB: SUWN) reached a new 52-week high today, trading at $1.245, up $0.170 (15.81%) from its previous close of $1.075.
The Company's previous 52-week high of $1.240 was set 2 days ago on February 22, 2006.
One year ago, the Company's shares closed at $0.150. The price has climbed more than 730 percent since then.
At the time of this alert, the stock had traded 2,124,100 shares via 233 trades, 20.24% below it's 20day average of 2,663,210 shares.
This new 52-week high currently puts the stock:
66.74% above its 20day Moving Average of $0.747
170.29% above its 50day Moving Average of $0.461
282.11% above its 100day Moving Average of $0.326
Man, every time I see a post on SUWN or see that the stock is up AGAIN, I start reaching for a phone to call a therapist. ;) I can't believe I sold this thing at .225 when I had already thought of Sunwin as the next AOB only better with their better diversification and the Stevia possibilities. Have to learn a lesson from this one. :) Hope you got some of this, Oliver!
Bas - I thought I was a genius for selling 60% of my shares the day it made the .97 high. I looked pretty smart for a while when it retraced to the .50's, but don't look so smart for selling the last 40% on the bounce at .64. I think it's way too extended to hold these gains though. I haven't seen many OTC stocks in my day go from .20 to over 1.30+ and hold the gain long-term. I think six months from now the SUWN chart will look a lot like BRVO's does today.
In this investment report, issued in November when the stock was at .22, the 12-month price target was .52.
http://www.sunwin.biz/temp/SUWN.OB_%20Report_NOV_121.pdf
I think SUWN's gotten a little ahead of itself. I may be eating those words in a month, we'll see.
Wow..... ;D
There have been some awesome penny picks lately
dang...i rode this from $0.65 and sold sometime back at $1.03, never looked back though...
i got back in today at break of $1.30
forgot the chart...here it is....closed near the 9 MA and looking good to break into higher territory...of course, gotta break earlier high of $1.51 first.
good luck to those in this one. ;)
to use a term i've seen around 'weeeeeeeeeeee' sure has been a fun ride. I'm not on it right now, but we'll see.
Sunwin International Neutraceuticals, Inc. (OTCBB:SUWN) traded as much as 8.21% over open on Thursday.
Sunwin International Neutraceuticals, Inc. ("Sunwin") (OTC BB: SUWN) is engaged in the areas of essential traditional Chinese medicine, 100% organic herbal medicine, neutraceutical products, natural sweetener (Stevioside), and animal medicine prepared from 100% organic herbal ingredients. As an industry leader in agricultural processing, Sunwin has built an integrated global firm with the sourcing and production capabilities to meet the needs of consumers throughout the world. Sunwin also makes such value-added products as specialty veterinary food ingredients and specialty feed ingredients. The Sunwin family works closely with consumer to provide a quality, value, and a hybrid mix of agricultural products and services that meet growing demand. In 2002, Sunwin was recognized as one of the first 2,000 state-level companies that China authorized as the most important innovative high-tech pioneer businesses by the Chinese central government. In 2002, Sunwin was awarded as one of 2002 state-level biological product manufacturers in China. In 2003, Sunwin ranked as one of the top 50 companies of China Animal Related Health Care Product Pharmaceutical Industry. In 2003, Sunwin received award of Shandong Top-Ten Innovative, High-Tech Businesses by the Province Government of Shandong. For more info about Sunwin, please visit http://www.sunwin.biz
I have asked myself at 0.8 and 1.24 $ if I should buy SUWN :P :'( :'( :'(
now we are @ 1.5 $ price level >:(
next pullback I will start to accumulate
cheers
Oliver
Form 10-K:
Form 10QSB for SUNWIN INTERNATIONAL NEUTRACEUTICALS, INC.
16-Mar-2006
Quarterly Report
ITEM 2.MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION
The following analysis of our consolidated financial condition and results of operations for the nine months ended January 31, 2006 and 2005, should be read in conjunction with the consolidated financial statements, including footnotes, and other information presented in our annual report of Form 10-KSB as filed with the Securities and Exchange Commission.
Overview
Effective February 1, 2004, Sunwin Tech Group, Inc. entered into a stock purchase agreement with Shandong Shengwang Pharmaceutical Corporation, Limited, a 90% shareholder of Qufu. Under this agreement, Sunwin Tech acquired 80% of the capital stock of Qufu in exchange for 100% of its capital stock which had a fair market value of $95,000. In April 2004, we acquired 100% of Sunwin Tech in exchange for approximately 17,000,004 shares of our common stock which resulted in a change of control of our company. The transaction has been accounted for as a reverse acquisition under the purchase method for business combinations. The combination of the two companies is recorded as a recapitalization of Qufu and we are treated as the continuing entity.
Though our subsidiaries, we manufacture and sell neutraceutical products which can be classified into three main product groups; (1) stevioside
- a 100% natural sweetener, (2) veterinary medicines and animal feed additives, and (3) traditional Chinese medicine formula extracts. All of our business and operations are located in the People's Republic of China.
We manufacture and sell stevioside, a 100% natural sweetener which is extracted from the leaves of the Stevia rebaudiana plant, a green herb plant of the Aster/Chrysanthemum family. We also purchase and resell finished stevioside product from third party manufacturers. Principal customers for this product are located in China and Japan where it is approved for use both as a food additive as well as a nutritional supplement. This product group represented approximately 46% of our total revenues for fiscal 2005 and 40% for the nine months ended January 31, 2006. China has grown into the world's largest exporter of stevioside, with volume exceeding 80% of the world's supply. We believe that we are one of the top three companies in China manufacturing stevioside.
We also manufacture and sell a comprehensive group of veterinary medicines including seven series of more than 200 products. These veterinary medicines include both traditional Chinese medicine and Western medicine, feed additives, feeds and disinfectors.
We are a leading advocator of preparing animal medicine from Chinese herbs, especially antivirus and feed additives. We are concentrating our efforts in this product category on developing and producing medicines which are relevant to the needs of the animal stock industry in the PRC, and developing special veterinary medicines made from pure traditional Chinese medicines or combining traditional Chinese medicine with Western medicine. This product group represented approximately 28% of our total revenues for fiscal 2005 and 30% for the nine months ended January 31, 2006. Our last product group includes the manufacture and sale of traditional Chinese medicines formula extracts that are used in products made for use by both humans and animals. This product group represented approximately 26% of our total revenues for fiscal 2005 and 30% for the nine months ended January 31, 2006.
-17-
ITEM 2.MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION (continued)
Our ability to significantly increase our revenues in any of these groups faces a number of challenges. In addition to the existing laws which limit the sale of stevioside to Western countries, the other two product groups operate in highly competitive environments. We estimate that there are more than 2,700 companies in China selling animal medicines and more than 200 companies in China that produce Chinese traditional medicines and extracts and refined chemical products. Our sale of products in these two product groups are concentrated on domestic customers therefore our ability to expand our revenues in these product groups is limited to a certain extent by economic conditions in the PRC. In addition, because we are dependent upon raw materials which are farmed, our ability to produce our products and compete in our markets is also subject to risks including weather and similar events which may reduce the amount of raw materials we are able to purchase from farmers as well as increased competition or market pressure which may result in reduced prices for our products. Our ability, however, to expand our revenues from the sale of stevioside is limited as the product is not approved for use as a food additive in most Western countries, including the United States, Canada and the European Union. In an effort to increase our competitive position within our market segment, we have built an additional stevioside manufacturing line in order to expand our stevioside production, upgraded our exiting manufacturing stevioside line, and relocated to a larger facility which became fully operational in November 2005 after experiencing delays associated with retooling, the installation of additional equipment, and final inspection delays. In addition, during fiscal year 2005 and the first two quarters of fiscal year 2006 we have been involved in reconstructing an additional veterinary production line into a new building which was put into full production in December 2005.
Through January 31, 2006, we have advanced and invested an aggregate of approximately $680,000 to be used for leasehold improvements and equipment towards the additional veterinary medicine manufacturing line and $1,550,000 towards the stevioside facility.
Even though we are a U.S. company, because all of our operations are located in the PRC, we face certain risks associated with doing business in that country. These risks include risks associated with the ongoing transition from state business ownership to privatization, operating in a cash-based economy, dealing with inconsistent government policies, unexpected changes in regulatory requirements, export restrictions, tariffs and other trade barriers, challenges in staffing and managing operations in a communist country, differences in technology standards, employment laws and business practices, longer payment cycles and problems in collecting accounts receivable, changes in currency exchange rates and currency exchange controls. We are unable to control the vast majority of these risks associated both with our operations and the country in which they are located and these risks could result in significant declines in our revenues and adversely effect our ability to continue as a going concern.
-18-
ITEM 2.MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION (continued)
Foreign Exchange Considerations
Because revenues from our operations in the PRC accounted for 100% of our consolidated net revenues for fiscal 2005 and fiscal 2004, how we report net revenues from our PRC-based operations is of particular importance to understanding our financial statements. Transactions and balances originally denominated in U.S. dollars are presented at their original amounts. Transactions and balances in other currencies are converted into U.S. dollars in accordance with Statement of Financial Accounting Standards (SFAS) No. 52, "Foreign Currency Translation," and are included in determining net income or loss. For foreign operations with the local currency as the functional currency, assets and liabilities are translated from the local currencies into U.S. dollars at the exchange rate prevailing at the respective balance sheet date. Revenues and expenses are translated at weighted average exchange rates for the period to approximate translation at the exchange rates prevailing at the dates those elements are recognized in the financial statements. Translation adjustments resulting from the process of translating the local currency financial statements into U.S. dollars are included in determining comprehensive loss.
The functional currency of our Chinese subsidiaries is the Chinese RMB, the local currency. The financial statements of the subsidiaries are translated to U.S. dollars using year-end rates of exchange for assets and liabilities, and average rates of exchange for the period for revenues, costs, and expenses. Net gains and losses resulting from foreign exchange transactions are included in the consolidated statements of operations and were not material during the periods presented. The cumulative translation adjustment and effect of exchange rate changes on cash at January 31, 2006 was approximately $36,500. Until 1994, the RMB experienced a gradual but significant devaluation against most major currencies, including U.S. dollars, and there was a significant devaluation of the RMB on January 1, 1994 in connection with the replacement of the dual exchange rate system with a unified managed floating rate foreign exchange system. Since 1994, the value of the RMB relative to the U.S. Dollar has remained stable and has appreciated slightly against the U.S. dollar. Countries, including the United States, have argued that the RMB is artificially undervalued due to China's current monetary policies and have pressured China to allow the RMB to float freely in world markets. On July 21, 2005, the PRC reported that it would have its currency pegged to a basket of currencies rather than just tied to a fixed exchange rate to the dollar. It also increased the value of its currency 2% higher against the dollar, effective immediately.
If any devaluation of the RMB were to occur in the future, returns on our operations in China, which are expected to be in the form of RMB, will be negatively affected upon conversion to U.S. dollars. Although we attempt to have most future payments, mainly repayments of loans and capital contributions, denominated in U.S. dollars, if any increase in the value of the RMB were to occur in the future, our product sales in China and in other countries may be negatively affected.
-19-
ITEM 2.MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION (continued)
Critical Accounting Policies
The discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
A summary of significant accounting policies is included in Note 1 to the audited consolidated financial statements on Form 10-KSB as filed with the Securities and Exchange Commission. Management believes that the application of these policies on a consistent basis enables us to provide useful and reliable financial information about the company's operating results and financial condition.
We record property and equipment at cost. Depreciation is provided using the straight-line method over the estimated economic lives of the assets, which are from five to twenty years. Expenditures for major renewals and betterments that extend the useful lives of property and equipment are capitalized. Expenditures for maintenance and repairs are charged to expense as incurred. We review the carrying value of long-lived assets for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets is measured by comparison of its carrying amount to the undiscounted cash flows that the asset or asset group is expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the property, if any, exceeds its fair market value.
We account for stock options issued to employees in accordance with the provisions of Accounting Principles Board ("APB") Opinion No. 25, "Accounting for Stock Issued to Employees," and related interpretations. As such, compensation cost is measured on the date of grant as the excess of the current market price of the underlying stock over the exercise price. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant. We adopted the disclosure provisions of SFAS No. 123, "Accounting for Stock-Based Compensation" and SFAS 148, "Accounting for Stock-Based Compensation -Transition and Disclosure", which permits entities to provide pro forma net income (loss) and pro forma earnings (loss) per share disclosures for employee stock option grants as if the fair-valued based method defined in SFAS No. 123 had been applied. We account for stock options and stock issued to non-employees for goods or services in accordance with the fair value method of SFAS 123.
-20-
ITEM 2.MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION (continued)
RESULTS OF OPERATIONS
NINE MONTHS ENDED JANUARY 31, 2006 AS COMPARED TO NINE MONTHS ENDED
JANUARY 31, 2005
Revenues
For the nine months ended January 31, 2006, our revenues were $11,065,853 as compared to $9,163,681 for the nine months ended January 31, 2005, an increase of $1,902,172 or approximately 21%. We attribute this increase in net revenues to an increase in revenues from the manufacture and sale of our traditional Chinese and animal medicine products of approximately $1,914,855 offset by a decrease in the sale of our natural sweetener, stevioside, of $12,683 as discussed below:
o The decrease in the sale of our natural sweetener, stevioside, was caused by the upgrade of our manufacturing equipment and relocation of our stevioside manufacturing facility, which has disrupted our revenue flows. We started to use this new manufacturing line in September 2005. However, due to delays associated with retooling, the installation of additional equipment and inspection delays, we became fully operational in November 2005. Our revenues decreased from $4,455,745 for the nine months ended January 31, 2005 to $4,443,062 for the nine months ended January 31, 2006, a less than 1% decrease. Until such time as the facility became fully operational, in the event we receive orders for Stevioside in excess of our manufacturing capacity, we purchased from other manufacturers and resold these goods to our customers to fill orders. We anticipate manufacturing 200 tons of stevioside and to resell 80 tons during fiscal year 2006. We believe that the market for stevioside remains strong as we see exports to Japan increasing.
o We experienced an increase in the revenues related to our traditional Chinese medicine products. Our revenues increased from $2,457,241 for the nine months ended January 31, 2005 to $3,348,114 for the nine months ended January 31, 2006, a 36.3% increase. Our gross profit rate has grown from 37.5% to 42% on this product due to the introduction of new products, and improved sales skills. Additionally, the Chinese central government issued a new rule for the Chinese Medicine industry stipulating that all manufactures should satisfy GMP standards in their production process by October 1, 2005. We believe that our facility is the first facility to complete this requirement in China which will help us maintain the reputation in this field and acquire bigger market share. Next year, we will be adding new products into the market and plan to start a new products series, natural dietary health food.
-21-
ITEM 2.MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION (continued)
o Revenues from our veterinary medicine grew 45% this period to $3,274,677 for the nine months ended January 31, 2006 as compared to $2,250,695 for the nine months ended January 31, 2005. However, in past nine months, our gross profit margins were at 33.2%, a decrease of 1.2% from the previous comparable period due to increased raw material costs. We believe that we will achieve major growth in veterinary medicine. The veterinary industry is regulated by the Chinese Central Government which recently issued a new regulation stipulating that all veterinary manufacturers should conform to the GMP production process standard by October 1, 2005. Among over 2,700 manufacturers in China, we estimate that only approximately 800 could accomplish this requirement on time. A significant market vacancy will be left by the companies that do not conform and pass the standard. We expect to complete construction and finish the inspection process on time. We expect to have eight production lines. We expect to obtain a greater market share in the fiscal year of 2006.
Cost of Sales and Gross Profit
For the nine months ended January 31, 2006, cost of sales amounted to $7,555,073 or 68.3% of net revenues as compared to cost of sales of $6,276,338 or 68.5% of net revenues for the nine months ended January 31, 2005, a percentage decrease of 0.2%. Gross profit for the nine months ended January 31, 2006 was $3,510,780 or 31.7% of revenues, as compared to $2,887,343, or 31.5% of revenues for the nine months ended January 31, 2005.
Operating Expenses
For the nine months ended January 31, 2006, total operating expenses were $1,542,858 as compared to $1,956,366 for the nine months ended January 31, 2005, a decrease of $413,508 or 21%.
Included in this decrease were:
* For the nine months ended January 31, 2006, we recorded income from the recovery of bad debt of $867,323 due to the collection of accounts receivable previously written off.
-22-
ITEM 2.MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION (continued)
* For the nine months ended January 31, 2005, we recorded consulting and stock-based consulting expense of $220,000 as compared to $278,517 for the nine months ended January 31, 2006, a decrease of $58,517 or 26%. This amount represented the value of shares of our common stock we issued or are issuable as compensation for consulting services being rendered to us. While we anticipate that we will enter into similar agreements during fiscal 2006, we cannot predict the amount of expense which will be attributable to such agreements. In July 2005, we entered into a one-year agreement with China Direct Investments, Inc. to provide business development and management services, effective May 1, 2005. In connection with this agreement, we were to issue 665,000 shares of our common stock payable on a quarterly basis on August 31, 2005, November 30, 2005, February 28, 2006 and May 1, 2006 for a total of 2,660,000. In November 2005, we issued 1,330,000 shares of common stock due under this consulting agreement. In January 2006, we issued the remaining 1,330,000 shares due under this contract and entered into a new consulting agreement with China Direct Investments, Inc. In connection with the issuance of 2,660,000 common shares under the original consulting agreement, the Company recorded stock-based consulting expense of $235,058 and deferred consulting expense of $203,933 to be amortized over the new contract term of 36-months. Effective January 1, 2006, we entered into a three-year agreement with China Direct Investments, Inc. to provide business development and management services. In connection with this new agreement, we issued 2,430,000 shares of common stock. We valued these services using the fair value of common shares on grant date at approximately $.23 per share and recorded deferred consulting expense of $558,900 to be amortized over the service period. For the nine months ended January 31, 2006, amortization of deferred consulting expense amounted to $21,190. The issuance of these shares will continue to increase stock-based consulting fees;
* For the nine months ended January 31, 2006, selling expenses amounted to $1,371,548 as compared to $987,267 for the nine months ended January 31, 2005, an increase of $384,281 or 39%. For the nine months ended January 31, 2006, we experienced an increase in commission expenses of approximately $173,600, increased travel and entertainment costs of approximately $102,700, an increase in shipping and freight of approximately $62,200, and other net increases in selling expenses of $45,800 related to increased selling activities.
* For the nine months ended January 31, 2006, general and administrative expenses were $760,116 as compared to $749,099 for the nine months ended January 31, 2005, an increase of $11,017 or 1.5%. The increase is primarily attributable to a decrease of approximately $161,000 in business development expenses incurred during the nine months ended January 31, 2005. This decrease was offset by an increase in travel and entertainment of approximately $113,300 and increases in general operating expenses such as management fees paid to a related party of $27,000 and office expenses associated with increased operations.
-23-
ITEM 2.MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION (continued)
For the nine months ended January 31, 2006, other income amounted to $152,771 as compared to other income of $24,881 for the nine months ended January 31, 2005. Other income for the nine months ended January 31, 2006 and 2005 was associated with income recognized from the collection of value-added taxes on certain of our products which we receive a tax credit.
For the nine months ended January 31, 2006, interest expense was $30,321 as compared to $55,608 for the nine months ended January 31, 2005, a decrease of $25,287 or 45%. Interest expense for the nine months ended January 31, 2006 and 2005 was associated with our borrowings.
For the nine months ended January 31, 2006, we recorded a benefit from income taxes of $523,906 as compared to a provision for income taxes of $(389,146) for the nine months ended January 31, 2005. In the current period, we received a waiver of income taxes from the local Chinese government, waiving income tax due through January December 2005. We do not expect to pay income taxes for fiscal 2006 and expect to receive an additional waiver for taxes through April 2006.
Our income before minority interest increased by $2,103,174 or 412% to $2,614,278 for the nine months ended January 31, 2006 as compared to $511,104 for the nine months ended January 31, 2005 primarily as a result of an increase in other income of $127,890, an increase in benefit from income axes of $913,052, and an increase in income of $867,323 from the recovery of bad debt previously written off.
For the nine months ended January 31, 2006, we reported a minority interest in income of subsidiary (Qufu) of $589,174 as compared to $158,017 for the nine months ended January 31, 2005. The minority interest in income of subsidiary is attributable to Qufu, which we allocate to the minority stockholders, had the effect of reducing our net income.
As a result of these factors, we reported net income of $2,025,104 or $.04 per share for the nine months ended January 31, 2006 as compared to net income of $353,087 or $.01 per share for the nine months ended January 31, 2005.
LIQUIDITY AND CAPITAL RESOURCES
At January 31, 2006, we had working capital of $7,225,260 and cash
and cash equivalents of $3,632,324. At January 31, 2006, our cash position
by geographic area is as follows:
United States $1,123,969
China 2,508,355
--------------
Total $3,632,324
==============
The Company presently has no need for other alternative sources of working capital and at this time, has no commitments, or plans to obtain additional capital. If in the future, the Company seeks to raise additional capital through the sale of equity securities, no assurances can be given that the Company will be successful in obtaining additional capital, or that such capital will be available on terms acceptable to the Company. Further, there can be no assurances that even if such additional capital is obtained, the Company will sustain profitability or positive cash flow.
-24-
ITEM 2.MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION (continued)
During fiscal 2005, we raised cash proceeds of $902,565 from the sale of our common stock. Additionally, during fiscal 2005, we reduced our balance that we advanced to customers by $1,018,862. During the nine months ended January 31, 2006, we received proceeds of $2,053,050 from the exercise of warrants.
At January 31, 2006, we had approximately $316,000 in short term loans payable maturing at or prior to February 2007. If we fail to obtain debt or equity financing to meet these obligations or fail to obtain extensions of the maturity dates of these debt obligations, our overall liquidity and capital resources will be adversely affected as a result of our efforts to satisfy these obligations.
Net cash provided by operating activities increased from $2,252,266 for the nine months ended January 31, 2005 to $2,314,557 for the nine months ended January 31, 2006. This increase is primarily attributable to:
* an increase of $1,672,017 in our net income,
* a decrease of $8,943 in depreciation and amortization as a result of the fact that certain property, plant and equipment was fully depreciated in the prior period.
* an increase of $66,312 in stock based compensation which reflects the increase in the payment of non-cash compensation to consultants during the 2006 period. We paid stock based compensation to consultants for business development services, management services, and investor relations services. We expect to issue additional common shares for consulting services in the future.
* an increase of $431,157 in minority interest which represents that portion of our net income which is attributable to the 20% of Qufu we do not own,
* a decrease of $796,512 in allowance for doubtful accounts which represents a decrease in our allowance for bad debt based on an analysis of our receivable balances and the collection of previously written-off accounts receivable,
* a decrease of $143,877 in accounts receivable as a result of collecting our receivables in a more timely manner and the application of advanced from customer to our accounts receivable balances,
* a decrease of $1,414,333 in inventory as a result of slow down of inventory production as we update our facilities. We expect our inventory levels to rise as we increase our stevioside production,
* a decrease of $688,779 in prepaid and other current assets, as a result of the receipt of inventory from advances previously made to suppliers of stevioside in preparation of our new stevioside production line,
* a decrease of $67,190 in due from related parties as a result of the receipt of inventory from advances previously made to related parties,
-25-
ITEM 2.MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION (continued)
* a decrease of $125,918 in accounts payable and accrued expenses as a result of the repayment of balances due from our cash provided by operations,
* a decrease of $915,093 in income tax payable as a result of the receipt of a tax waiver in the current period,
* an increase of $301,753 in advances from customers which includes an increase in prepayments from our stevioside customers due to an increase in production and shipments as we added and upgraded manufacturing lines. We expect advances from customers to increase to approximately $1,000,000 as stevioside production increases.
Net cash used in investing activities increased to $2,156,597 for the nine months ended January 31, 2006 as compared to $1,484,609 for the nine months . . .
good news out:
Sunwin International Neutraceuticals Receives Purchase Orders Over 150 Tons of Stevia, a 100% Increase Compared to the Same Period of 2005
Tuesday April 25, 8:30 am ET
Company Forecasts Rapidly Increased Global Demand for Stevia
QUFU, CHINA--(MARKET WIRE)--Apr 25, 2006 -- Sunwin International Neutraceuticals, Inc. (OTC BB: SUWN), an industry leader in the production and distribution of Chinese herbs, veterinary medicines and low calorie sweetener (Stevia) in China, announced today that the company's Stevia production at their newly constructed facility has reached 22 to 25 tons per month or 260 to 300 tons per year following a major renovation effort commenced in 2005.
In the first three months of 2006, the company has received purchase orders in excess of 125 tons of Stevia, a 100% increase compared to same period in 2005, or 80% of Sunwin's Stevia production for the entire 2005 fiscal year. The company's production of Stevia during 2005 was reduced due to construction of the new Stevia production facility.
Due to increase global demand and consumption of Stevia, Sunwin plans to outsource a certain percentage of Stevia production to third parties. Management estimates to produce 260 tons to 300 tons of Stevia at our own new facility while outsourcing an additional 150 tons to 200 tons for fiscal 2007. Sunwin's Stevia division alone could achieve approximately $12 to $15 million in annual sales in the coming fiscal year, prior to any potential acquisitions, and the potential Stevia sales in North America.
Stevia, a natural sweetener extracted from the leaves of the Stevia rebaudiana plant, is used as a food additive in a wide variety of products such as beverages, pastries, dairy products, candies, confections, and medicinal products in Japan, China, Malaysia, Israel, South Korea, the Pacific Rim, Brazil , and numerous Latin American countries.
Japan, known worldwide as having healthy dietary habits with a population of over 127 million people, utilizes Stevia for 30% to 40% of their entire sweetener consumption including sugar. Stevia is used as a sweetener by some of the largest North American food and beverage manufacturers in their Japanese production facilities. The population of countries that currently use Stevia as a sweetener exceeds two billion worldwide. Currently the FDA requires Stevia to be labeled as a dietary supplement for sale in the U.S.
Mr. Laiwang Zhang, Chairman and President of Sunwin International, commented, "We believe Stevia is the sweetener of the future. The human body does not metabolize the sweet glycosides (they pass right through the normal elimination channels) from the leaf or any of its processed forms; therefore, the body retains few if any calories from Stevia. For those who have blood sugar, blood pressure, diabetic or weight problems, Stevia is an excellent supplement to their daily diet."
Mr. Zhang concluded, "Our goal is to increase Stevia production to 800 to 1,000 tons per year by the end of 2007. Furthermore, we plan to move forward with our marketing campaign to access the U.S. consumer market. Lastly we will continue our M&A strategy as we are presently reviewing several Stevia production facilities for acquisition."
It seems like one day of good news is not enough for SUWN. Resistance at 1.21 is set and a close above it would also mean close above 50MA, I'd like to see that. Volume as seriously declined since the big move to 1.60-1.70.
I bought SUWN at 1.20 on 3/6, but plan on selling if there is a close below 1.05 tomorrow. let's hope not.
livana, i suggest you use full/slow stochastics insted of the fast stochastics...to sort of avoid the many wiggles you see. good luck....the volume is very low, not much interest in this stock for now...
if you do have capital to spare....get in and play the ones in the spotlight...like the ethamol sector...you can trade them stocks and make some quick cash...i'm sure you'd like that, right? ;)
Ethanol, huh?
I've been meaning to look into that... I did free up some funds, by dumping UPDA (I waited way to long).
Thanks for the sto advice.
Quote from: Livana on April 26, 2006, 06:58:59 PM
Ethanol, huh?
I've been meaning to look into that... I did free up some funds, by dumping UPDA (I waited way to long).
Thanks for the sto advice.
hey Liv,
I listen to cnbc all day while i'm working out of my house (nice, huh?), and they've been talking ethanol for about a month or two and are now really talking it up big time. gas is going up because of it, farmers are getting .15¢ a bushel more for corn (on top of their subsidies), and the green companies producing ethanol are seeing bigger pps in the last 6 to 8 weeks. if you take a look at XTHN, it's a new york co. w/ plans to build 5 more ethanol plants. it went from $5 to $16 in a little over a month. and the best part, the government brought all of this on w/ their mandadatory "scrubber" bill. i think you could definetly pop in an out of VRDM, GSHF and make a nice profit....check those posts out...
hey RV - I work from my house too. But I seem to be a little busier than you cause I don't have time to listen to CNBC all day... ;D ::) Just kidding with you...
I did hear a little about it too. Was it CNBC or MSNBC? Can't remember. Anyway, The guy on there was saying that a gallon of E85 goes for a whole 20 cents less than regular unleaded!??! Did I hear that right? I though that on top of being so much environmentally friendly, ethanol was also going to be so much cheaper.
We should probably start a thread on that somewhere else... it seems like a good topic to talk about.
Dutton Associates Announces Investment Opinion: Sunwin International Neutraceuticals Strong Speculative Buy in Initiating Coverage by Dutton Associates
Monday , May 08, 2006 16:50 ET
EL DORADO HILLS, Calif., May 08, 2006 (BUSINESS WIRE) -- Dutton Associates initiates coverage of Sunwin International Neutraceuticals (OTCBB: SUWN) with a Strong Speculative Buy rating and a price target of $1.85. The 23-page report by Dutton senior analyst Stanley Ng is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial portals.
We are initiating coverage of Sunwin International Neutraceuticals, Inc. with a Strong Speculative Buy rating. The Company is principally engaged in the development, production and marketing of nutraceutical products, with a prime focus on calorie-free natural sweeteners, traditional Chinese medicine (TCM)-based veterinary medications and animal additives, and TCM-formula extracts for both human and animals. Most of these products are sold on a wholesale basis in the domestic market via a nationwide distribution network, as well as by exporting to overseas markets. In our opinion, the Company offers investors a good opportunity to invest in the huge and growing nutraceutical market, which comprises a wide variety of food and beverage products, dietary supplements and medications, as well as animal feeds and veterinary remedies. To strengthen its market position and to enhance its competitiveness, the Company is aggressively increasing its production capacity and marketing channels in North America for its stevioside, a calorie-free natural sweetener. Meanwhile, large capital expenditures to upgrade its production facilities to comply with the latest Good Manufacturing Practice (GMP) requirements introduced by the People's Republic of China (PRC) would enable it to capture greater market shares for its veterinary medicine and TCM products.
23 slides analysis:
http://www.jmdutton.com/research/suwn/reports/suwn_report_050806.pdf
>:D
Hi,
a rebound for SUWN ?
Technical analyst :
Candelstick : Morning star pattern (bullish)
Technical indicator : Price is oversold with an increasing RSI (RSI(14))
Support : Price around MA(200). MA(200) as good support.
Fibonacci : 61.8 ratio (very good).
Stop-loss :
0.625
Target :
Look at doc...
Conclusion :
Few risk and possible good reward.
By and good trades.
My doc...
Back above the 200-day MA ....
Now we need a volume pop!
Support @ 0.79...0.73...0.67
Resistance @ 0.91...1.04...1.13
Candlestick Analysis
Today's Candlestick Patterns:
White Closing Marubozu
Today a White Closing Marubozu was formed. This shows that the day opened and then prices went lower slightly, however it was followed by a rally that drove the prices over the opening price and the rally continued all day ending with a closing price equal to the high of the day.
Excuse me, it is past the time to update....... ;)
A few of the Headlines.
• Sunwin International Neutraceuticals Receives Approval From Health Canada for Distribution of Products in Canada
Market Wire (Mon, Apr 16)
• Sunwin International Added to the Ludlow China SmallCap Index
Market Wire (Mon, Mar 12)
• Sunwin Stevia International Receives Purchase Order for OnlySweet(TM) for Utilization in the Food Services Industry
Market Wire (Wed, Apr 25)
Link to the News....... http://finance.yahoo.com/q/h?s=SUWN.OB
Support @ 0.63...0.59...0.52
Resistance @ 0.67...0.70...0.75...0.87
MACD is Bullish
52wk Range: 0.41 - 1.24
Volume: 1,343,305
Avg Vol (3m): 162,430
On this 6 month chart a,
Falling Wedge (reversal) Pattern.
The falling wedge is a bullish pattern that begins wide at the top and contracts as prices move lower. This price action forms a cone that slopes down as the reaction highs and reaction lows converge. In contrast to symmetrical triangles, which have no definitive slope and no bias, falling wedges definitely slope down and have a bullish bias. However, this bullish bias cannot be realized until a resistance breakout.
The falling wedge can also fit into the continuation category. As a continuation pattern, the falling wedge will still slope down, but the slope will be against the prevailing uptrend. As a reversal pattern, the falling wedge slopes down and with the prevailing trend. Regardless of the type (reversal or continuation), falling wedges are regarded as bullish patterns.
As with rising wedges, the falling wedge can be one of the most difficult chart patterns to accurately recognize and trade. When lower highs and lower lows form, as in a falling wedge, a security remains in a downtrend. The falling wedge is designed to spot a decrease in downside momentum and alert technicians to a potential trend reversal. Even though selling pressure may be diminishing, demand does not win out until resistance is broken. As with most patterns, it is important to wait for a breakout and combine other aspects of technical analysis to confirm signals.
Moving....... 8)
Broke through the resistance @ 0.87....... ;D
Next Resistance @ $1.00...1.20...1.40
MACD is Bullish
Press Release Source: Sunwin International Neutraceuticals, Inc.
Sunwin Stevia International's OnlySweet(TM) Stevia to Be Used in a Line of Low Calorie Cola and Soft Drinks
Wednesday June 20, 7:24 am ET
TAMARAC, FL--(MARKET WIRE)--Jun 20, 2007 -- Sunwin Stevia International Corp., a wholly owned subsidiary of Sunwin Neutraceuticals, Inc. (OTC BB:SUWN.OB - News), announced today that it has received a purchase order for its OnlySweet(TM) stevia to be used in a line of low calorie Cola, Orange Soda, and Lemon Lime Twist Soft Drinks.
Steven Silbert, Executive Vice President of Sunwin Stevia International Corp., states, "We have been approached by numerous companies that have expressed an interest in utilizing stevia produced by our parent company, Sunwin Neutraceuticals, as well as our blended product OnlySweet(TM) for utilization in the food and beverage industry. In the United States these products would be labeled as a dietary supplement in accordance with FDA requirements. While our focus is on the distribution and sales growth of OnlySweet(TM), we also understand the value of positioning our product as an ingredient in a wide variety of 'All Natural' dietary supplement products. We are currently assessing the market, as well as the companies that have approached us, to ensure that any potential strategic relationships will benefit the company and enhance our product offerings over the coming years. The recent attention regarding stevia, due to articles in several national publications, has sparked a flurry of activity which we believe will lead to significant revenue opportunities in the near future."
ABOUT ONLYSWEET(TM)
OnlySweet(TM) is a proprietary blend that comes in 100ct and 200ct 1-gram packages. The company is currently working on a baking product that is scheduled to be available to consumers in the near future. The product is currently labeled as a dietary supplement in accordance with FDA requirements. OnlySweet(TM) is all natural and contains Zero Calories.
OnlySweet(TM) is blended in an FDA approved facility in the greater Chicago area that provides similar services to some of the most well known brands in the food industry. They insure that the highest levels of quality control protocol are performed on each and every run of our product.
The stevia in OnlySweet(TM) comes from its parent company Sunwin International Neutraceuticals Inc. (OTC BB:SUWN.OB - News), one of the world's largest manufacturers and distributors of stevia in the world. This insures consistency and quality in every package of our product. We believe that OnlySweet(TM) is the best tasting stevia product on the market. Our product will be priced between 40 to 50% less then the majority of our competitors, therefore making it affordable to the masses.
About Sunwin Stevia International Corp.
Sunwin Stevia International Corp., a wholly owned subsidiary of Sunwin International Neutraceuticals, Inc. (OTC BB:SUWN.OB - News), is the maker of the Only Sweet(TM) line in North America sold in major grocery outlets in North America. For more information about Only Sweet(TM), please visit http://www.onlysweet.com. For more info about Sunwin family, please visit http://www.sunwin.biz
Safe Harbor Statement
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations or beliefs, including, but not limited to, statements concerning the Company's operations, financial performance and, condition. For this purpose, statements that are not statements of historical fact may be deemed to be forward-looking statements. The Company cautions that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, but not limited to, the impact of competitive products, pricing and new technology; changes in consumer preferences and tastes; and effectiveness of marketing; changes in laws and regulations; fluctuations in costs of production, and other factors as those discussed in the Company's reports filed with the Securities and Exchange Commission from time to time. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
Contact:
CONTACT:
Steven Silbert
Executive Vice President
Tel: 954.724.2944
[email protected] --------------------------------------------------------------------------------
Source: Sunwin International Neutraceuticals, Inc.
Take note.......
52wk Range: 0.41 - 1.04
Volume: 2,658,067
Avg Vol (3m): 509,879
Moving north....keep track...
52wk Range: 0.41 - 1.04
Volume: 768,439
Avg Vol (3m): 567,736
Press Release Source: Sunwin International Neutraceuticals, Inc.
Sunwin International Neutraceuticals in Contract to Supply 120 Tons of Premium Stevia Valued at $4 to $5 Million
Monday July 2, 7:00 am ET
QUFU, CHINA--(MARKET WIRE)--Jul 2, 2007 -- Sunwin International Neutraceuticals, Inc. (OTC BB:SUWN.OB - News), a leader in the production and distribution of Chinese herbs, veterinary medicines and one of the world's leading producers and distributors of all natural, zero calorie Stevia in China, announced today that it has entered into a contract to sell 120 tons of premium stevia to be manufactured at its new facility to a South Korean company. Sunwin has completed the first production run at its new premium stevia facility and is satisfied that the quality and control of the new facility met all of the company's expectations. Sunwin intends to begin full production operations beginning July 1.
The contract with the South Korean company to supply 120 tons of the premium stevia is valued at $4 to $5 million and is scheduled to be delivered over the next 12 months at a rate of about 10 tons per month. The order accounts for 40% of the designed production capabilities of the newly built facility.
The new facility uses proprietary technologies developed by Sunwin to process the seed of the Stevia rebaudiana plant, enabling the company to produce what it believes to be one of the highest-grade stevia extracts ever produced. In addition, Sunwin's scientists have developed proprietary technologies for stevia purification and production in order to further insure consistency in the quality of stevia delivered by Sunwin.
Sunwin anticipates additional production from the facility will be utilized to support Sunwin's new product offerings, marketed under the trademark name "OnlySweet(TM)" in North America, scheduled to be available in the second quarter of 2007 through over 3,000 grocery stores in the U.S.
Laiwang Zhang, President, and Chairman of Sunwin International Neutraceuticals, commented, "We are very pleased that our newly constructed facility is now operational to produce our premium stevia. The worldwide demand for our premium stevia continues to grow and management foresees additional facility expansion in the near future, as we plan to meet expected demand from the usage of Stevia in the beverage and food industries in the U.S. in 2008 and beyond. We believe our all natural, zero calorie stevia will become a mainstay sweetener throughout the world and we intend to be well positioned to be the leading producer in this rapidly growing industry."
About Sunwin International Neutraceuticals, Inc.
Sunwin International Neutraceuticals (OTC BB:SUWN.OB - News) engages in the areas of essential traditional Chinese medicine, zero calorie natural sweetener (Stevia), and veterinary medicines and feeds prepared from 100% organic herbal ingredients. As an industry leader in agricultural processing, Sunwin has built an integrated global firm with the sourcing and production capabilities to meet the needs of consumers throughout the world. Sunwin also makes such value-added products as specialty veterinary food ingredients and specialty feed ingredients. For more info about Sunwin, please visit http://www.sunwin.biz
About OnlySweet(TM)
OnlySweet(TM) is a proprietary product blended with Stevioside (stevia), a natural sweetener, extracted from the leaves of the Stevia rebaudiana plant. OnlySweet(TM) is distributed through Sunwin Stevia International Corp. It is used as a food additive in a wide variety of products, such as beverages, pastries, dairy products, confections, and medicinal products in Japan, China, Malaysia, Israel, South Korea, Brazil, and other countries. In the United States, OnlySweet(TM) is a dietary supplement sold in boxes of 100 and 200 sachets. It has zero calories and does not significantly alter blood sugar levels. OnlySweet(TM) is unique because its stevia only comes directly from Sunwin International Neutraceuticals (OTC BB:SUWN.OB - News), one of the world's largest stevia manufacturers, assuring consistency and purity.
Safe Harbor Statement
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations or beliefs, including, but not limited to, statements concerning the Company's operations, financial performance and, condition. For this purpose, statements that are not statements of historical fact may be deemed forward-looking statements. The Company cautions that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, but not limited to, the impact of competitive products, pricing and new technology; changes in consumer preferences and tastes; and effectiveness of marketing; changes in laws and regulations; fluctuations in costs of production, and other factors as those discussed in the Company's reports filed with the Securities and Exchange Commission from time to time. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
Contact:
CONTACT:
Steven Silbert
Executive Vice President
Tel: 954.724.2944
[email protected]--------------------------------------------------------------------------------
Source: Sunwin International Neutraceuticals, Inc.
Buy any Dip.......